leadf
logo-loader
viewBioasis Technologies Inc.

Bioasis Technologies secures patents in key global markets

Bioasis Technologies, Inc . (OTCQB:BIOAF) (CVE:BTI) CEO Deborah Rathjen sat down with Proactive's Christine Corrado at the Biotech Showcase 2020 in San Francisco. The Guilford, Connecticut-based company is developing a proprietary technology to delivery therapeutics across the blood brain barrier and treating CNS disorders in brain cancers and neurodegenerative diseases.

Quick facts: Bioasis Technologies Inc.

Price: 0.2975 USD

OTCQB:BIOAF
Market: OTCQB
Market Cap: $20.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Bioasis Technologies Inc. named herein, including the promotion by the Company of Bioasis Technologies Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Bioasis Technologies forms 'exciting' licensing agreement with Chiesi Global...

Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) CEO Deborah Rathjen tells Proactive the Canada-based firm and Italy-based Chiesi Global Rare Diseases have entered into a licensing agreement for Bioasis’ xB3 BBB platform technology to treat rare diseases with a focus on four undisclosed...

on 06/30/2020

2 min read